Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: A HORIZONS-AMI substudy

Journal of Thrombosis and Thrombolysis

Volumn 34, Issue 2, 2012, Pages 165-179

  Claessen, Bimmer E ^a,b,c,d   Stone, Gregg W ^a,b,c,e   Mehran, Roxana ^a,b,c   Witzenbichler, Bernhard ^f   Brodie, Bruce R ^g   Wöhrle, Jochen ^h   Witkowski, Adam ⁱ   Guagliumi, Giulio ^j   Zmudka, Krzysztof ^b,c   Henriques, José P S ^d   Tijssen, Jan G P ^d   Sanidas, Elias A ^a,b,c,e   Chantziara, Vasiliki ^a,b,c,e   Hakim, Diaa ^a,b,c,e   Leon, Selene ^a,b,c   Xu, Ke ^a,b,c   Dangas, George D ^a,b,c  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e NewYork Presbyterian Hospital   (United States)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g LeBauer CV Research Foundation   (United States)

^h UNIVERSITY OF ULM   (Germany)

ⁱ INSTITUTE OF CARDIOLOGY   (Poland)

^j Ospedali Reuniti di Bergamo   (Italy)

more..

Author keywords

Biomarkers; Drug eluting stents; In stent restenosis; Primary percutaneous coronary intervention

Indexed keywords

CARDIOTROPHIN 1; GELATINASE B; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; MYELOPEROXIDASE; PACLITAXEL; PLACENTAL GROWTH FACTOR;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TARGET LESION REVASCULARIZATION;

AGED; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CYTOKINES; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; PEROXIDASE; PREGNANCY PROTEINS; TUBULIN MODULATORS;

EID: 84865146148     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0706-x     Document Type: Article

References (25)

1. Stone GW, Grines CL, Cox DA et al (2002) Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346:957-966 (Pubitemid 34983245)
2. Brar SS, Leon MB, Stone GW et al (2009) Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol 53:1677-1689
3. De LG, Stone GW, Suryapranata H et al (2009) Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Int J Cardiol 133:213-222
4. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R (2010) In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 56:1897-1907
5. Libby P, Clinton SK (1992) Cytokines as mediators of vascular pathology. Nouv Rev Fr Hematol 34(Suppl):S47-S53 (Pubitemid 23274737)
6. Hwang CW, Levin AD, Jonas M, Li PH, Edelman ER (2005) Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation 111:1619-1626 (Pubitemid 40525161)
7. Mehran R, Brodie B, Cox DA et al (2008) The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. Am Heart J 156:44-56 (Pubitemid 351862292)
8. Stone GW, Witzenbichler B, Guagliumi G et al (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218-2230 (Pubitemid 351724451)
9. Stone GW, Lansky AJ, Pocock SJ et al (2009) Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 360:1946-1959
10. Stone GW, Witzenbichler B, Guagliumi G et al (2011) Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 377:2193-2204
11. Nutritional anaemias (1968) Report of a WHO scientific group. World Health Organ Tech Rep Ser 405:5-37
12. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
13. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R (1999) Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 19:2364-2367 (Pubitemid 29477837)
14. Kleemann R, Zadelaar S, Kooistra T (2008) Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 79:360-376
15. Schieffer B, Selle T, Hilfiker A et al (2004) Impact of interleukin- 6 on plaque development and morphology in experimental atherosclerosis. Circulation 110:3493-3500 (Pubitemid 39602229)
16. Pennica D, King KL, Shaw KJ et al (1995) Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA 92:1142-1146
17. Khurana R, Moons L, Shafi S et al (2005) Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 111:2828-2836 (Pubitemid 40791556)
18. Heeschen C, Dimmeler S, Fichtlscherer S et al (2004) Prognostic value of placental growth factor in patients with acute chest pain. J Am Med Assoc 291:435-441 (Pubitemid 38129747)
19. Feldman LJ, Mazighi M, Scheuble A et al (2001) Differential expression of matrix metalloproteinases after stent implantation and balloon angioplasty in the hypercholesterolemic rabbit. Circulation 103:3117-3122 (Pubitemid 32587860)
20. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA (1994) Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 75:539-545 (Pubitemid 24256415)
21. Nicholls SJ, Hazen SL (2005) Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 25:1102-1111 (Pubitemid 40776595)
22. Dibra A, Ndrepepa G, Mehilli J et al (2005) Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents. Am J Cardiol 95:1238-1240 (Pubitemid 40616430)
23. Ferrante G, Niccoli G, Biasucci LM et al (2008) Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. Cardiovasc Revasc Med 9:156-165 (Pubitemid 351910724)
24. Lee SW, Park SW, Kim YH et al (2011) A randomized, doubleblind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drugeluting stent implantation in long coronary lesions results from the DECLARE-LONG II (drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions) trial. J Am Coll Cardiol 57:1264-1270
25. Lee SW, Park SW, Kim YH et al (2008) Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol 51:1181-1187